Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ruxolitinib Phosphate

FDA-approved product (tablet, oral), marketed as Leqselvi, Jakafi, Jakafi Xr and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ruxolitinib Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alopecia areata
  • Cancer
  • Eczematoid dermatitis
  • Graft versus host disease
  • Myelofibrosis
  • Myeloproliferative disorder
  • Neoplasm
  • Polycythemia vera
  • Primary myelofibrosis
  • Vitiligo

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Agents for dermatitis, excluding corticosteroids; Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor; Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ruxolitinib Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ruxolitinib Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

    NCT04269850 · start 2019-09-01

    Registered record
    Registry ID
    NCT04269850
    Conditions
    Intestinal GVHD
    Interventions
    allogeneic fecal microbiota; Ruxolitinib; Methylprednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2019-09-01
    Completion
    2024-11-27
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal GVHD
    Interventionallogeneic fecal microbiota; Ruxolitinib; Methylprednisone
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

    NCT03773107 · start 2019-01-03

    Registered record
    Registry ID
    NCT03773107
    Conditions
    Multiple Myeloma
    Interventions
    Carfilzomib; Ruxolitinib; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-01-03
    Completion
    2024-02-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionCarfilzomib; Ruxolitinib; Dexamethasone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

    NCT03745638 · start 2018-12-20

    Registered record
    Registry ID
    NCT03745638
    Conditions
    Atopic Dermatitis
    Interventions
    Ruxolitinib Cream; Vehicle Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-12-20
    Completion
    2020-12-01
    Enrolment
    631

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionRuxolitinib Cream; Vehicle Cream
    PhasePhase 3
    Registry statusCompleted

  • Ruxolitinib for Premalignant Breast Disease

    NCT02928978 · start 2018-05-13

    Registered record
    Registry ID
    NCT02928978
    Conditions
    Ductal Carcinoma In Situ; Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma In Situ
    Interventions
    Ruxolitinib; Placebo (for Ruxolitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-13
    Completion
    2024-09-18
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuctal Carcinoma In Situ; Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma In Situ
    InterventionRuxolitinib; Placebo (for Ruxolitinib)
    PhasePhase 2
    Registry statusCompleted

  • Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

    NCT03386214 · start 2018-04-23

    Registered record
    Registry ID
    NCT03386214
    Conditions
    Myelofibroses
    Interventions
    Pevonedistat; Ruxolitinib; Peripheral blood draw; Skin biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-04-23
    Completion
    2021-10-04
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibroses
    InterventionPevonedistat; Ruxolitinib; Peripheral blood draw; Skin biopsy
    PhasePhase 1
    Registry statusTerminated

  • A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

    NCT03287245 · start 2018-02-21

    Registered record
    Registry ID
    NCT03287245
    Conditions
    Polycythemia Vera
    Interventions
    Idasanutlin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-21
    Completion
    2020-03-03
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera
    InterventionIdasanutlin
    PhasePhase 2
    Registry statusTerminated

  • Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

    NCT02876302 · start 2018-01-24

    Registered record
    Registry ID
    NCT02876302
    Conditions
    Inflammatory Breast Cancer (IBC)
    Interventions
    Ruxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2024-10-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Breast Cancer (IBC)
    InterventionRuxolitinib; Paclitaxel; Doxorubicin; Cyclophosphamide
    PhasePhase 2
    Registry statusCompleted

  • VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

    NCT03120624 · start 2017-09-15

    Registered record
    Registry ID
    NCT03120624
    Conditions
    Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7
    Interventions
    Biopsy; Computed Tomography; Fluorine F 18 Tetrafluoroborate; Pharmacological Study; Positron Emission Tomography; Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter; Ruxolitinib Phosphate; Technetium Tc-99m Sodium Pertechnetate; Biospecimen Collection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2017-09-15
    Completion
    2028-01-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma +6 more
    InterventionBiopsy; Computed Tomography; Fluorine F 18 Tetrafluoroborate; Pharmacological Study +5 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

    NCT04526223 · start 2017-04-20

    Registered record
    Registry ID
    NCT04526223
    Conditions
    Time of Hematopoietic Reconstruction
    Interventions
    comprehensive treatment regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-04-20
    Completion
    2022-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTime of Hematopoietic Reconstruction
    Interventioncomprehensive treatment regimen
    PhaseNot applicable
    Registry statusUnknown

  • Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

    NCT03117751 · start 2017-03-29

    Registered record
    Registry ID
    NCT03117751
    Conditions
    Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
    Interventions
    Prednisone; Vincristine; Daunorubicin; Pegaspargase; Erwinase®; Cyclophosphamide; Cytarabine; Mercaptopurine; Dasatinib; Methotrexate; Blinatumomab; Ruxolitinib; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Clofarabine; Vorinostat; Idarubicin; Nelarabine; Thioguanine; Asparaginase Erwinia chrysanthemi (recombinant)-rywn; Calaspargase Pegol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2017-03-29
    Completion
    2028-09-30
    Enrolment
    790

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma
    InterventionPrednisone; Vincristine; Daunorubicin; Pegaspargase +19 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Ruxolitinib Combined With Dexamethasone for HLH

    NCT03795909 · start 2017-03-01

    Registered record
    Registry ID
    NCT03795909
    Conditions
    Hemophagocytic Lymphohistiocytosis
    Interventions
    Ruxolitinib; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2017-03-01
    Completion
    2022-03-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemophagocytic Lymphohistiocytosis
    InterventionRuxolitinib; Dexamethasone
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    NCT03110822 · start 2017-02-01

    Registered record
    Registry ID
    NCT03110822
    Conditions
    Multiple Myeloma
    Interventions
    Ruxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2017-02-01
    Completion
    2027-02
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionRuxolitinib Oral Tablet [Jakafi]; Lenalidomide; Methylprednisolone
    PhasePhase 1
    Registry statusRecruiting

  • A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

    NCT02953678 · start 2016-12-30

    Registered record
    Registry ID
    NCT02953678
    Conditions
    Graft-versus-host Disease (GVHD)
    Interventions
    Ruxolitinib; Prednisone or methylprednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-30
    Completion
    2019-08-14
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-versus-host Disease (GVHD)
    InterventionRuxolitinib; Prednisone or methylprednisolone
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure

    NCT02912884 · start 2016-09

    Registered record
    Registry ID
    NCT02912884
    Conditions
    Polycythemia Vera; Thrombocythemia, Essential
    Interventions
    No cytoreductive vs cytoreductive drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-09
    Completion
    2020-10-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycythemia Vera; Thrombocythemia, Essential
    InterventionNo cytoreductive vs cytoreductive drugs
    PhaseNot recorded
    Registry statusCompleted

  • Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

    NCT02072057 · start 2014-04-20

    Registered record
    Registry ID
    NCT02072057
    Conditions
    Cancer Cachexia
    Interventions
    Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-04-20
    Completion
    2018-11-30
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Cachexia
    InterventionRuxolitinib
    PhasePhase 2
    Registry statusTerminated